Akero Therapeutics

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

Resalis Therapeutics

This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.

Carmot Therapeutics

This biotechnology company develops drug therapies to treat metabolic diseases, such as obesity and diabetes, for patients with these conditions.

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

89bio (NASDAQ: ETNB)

This biopharmaceutical company develops pegozafermin to treat patients with liver and cardio-metabolic diseases, including metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.